GaBI Journal-Generics and Biosimilars Initiative Journal
Scope & Guideline
Bridging Research and Practice in Pharmaceuticals
Introduction
Aims and Scopes
- Biosimilars Development and Approval Processes:
The journal extensively covers the methodologies and regulatory frameworks for the development and approval of biosimilars, emphasizing the need for rigorous standards in clinical trials and post-market surveillance. - Economic and Policy Implications:
Research published in the journal often explores the economic aspects of biosimilars and generics, including pricing strategies, market access, and the impact of healthcare policies on patient access to these medications. - Pharmacokinetics and Bioequivalence Studies:
A significant focus is placed on pharmacokinetic studies and bioequivalence evaluations, providing insights into clinical research methodologies that ensure the safety and efficacy of biosimilars compared to their reference products. - Public Perception and Acceptance:
The journal examines the attitudes and perceptions of healthcare professionals and patients towards biosimilars, highlighting factors that influence their acceptance and usage in clinical practice. - Global Perspectives on Biosimilars:
Research articles often present a global view on biosimilars, discussing market trends, regulatory challenges, and successful case studies from various countries.
Trending and Emerging
- Healthcare Policy and Drug Pricing:
Recent publications are increasingly addressing the impact of healthcare policies, such as drug price negotiations, on patient access to medications, highlighting the relevance of economic factors in the biosimilars market. - Ethnic Sensitivity and Clinical Development:
There is a growing emphasis on assessing ethnic sensitivity in clinical trials for biosimilars, which is crucial for ensuring that these products are safe and effective across diverse populations. - Pharmacovigilance and Post-Market Studies:
The focus on pharmacovigilance and long-term post-market studies is increasing, reflecting a demand for robust safety data and monitoring as biosimilars gain market share. - Interchangeability and Substitution Policies:
A trend towards more nuanced discussions around interchangeability, substitution policies, and the implications of switching between biosimilars and their reference products is emerging. - Innovations in Manufacturing and Quality Control:
There is a rising interest in innovative manufacturing processes and quality control measures for biosimilars, indicating a shift towards ensuring product integrity and reliability.
Declining or Waning
- Traditional Generic Drug Development:
There has been a noticeable decline in articles specifically focused on traditional generic drug development, as the journal shifts its attention more towards biosimilars and their unique challenges. - Static Regulatory Frameworks:
Research discussing established regulatory frameworks without innovative updates or challenges has decreased, reflecting a transition towards more dynamic discussions on evolving regulations in the biosimilar space. - Single-Country Case Studies:
Publications that focus solely on case studies from individual countries have become less frequent, as the journal increasingly emphasizes comparative studies and global perspectives. - Historical Analysis of Drug Markets:
Fewer articles are dedicated to historical analyses of drug markets, indicating a shift towards more current and forward-looking discussions regarding biosimilars and generics.
Similar Journals
Journal of Pioneering Medical Sciences
Bridging gaps in medical science with pioneering studies.Journal of Pioneering Medical Sciences, published by JPMS PUBL in Karachi, Pakistan, stands as a vital resource in the field of medical research and practice. Established in 2012, this Open Access journal fosters the dissemination of innovative findings and groundbreaking studies that contribute to the advancement of medical science. With an ISSN of 2309-7981 and a commitment to rigorous peer-review, the journal encompasses a diverse range of topics, aiming to bridge knowledge gaps and promote interdisciplinary dialogue among healthcare professionals and researchers. Although it currently lacks an H-index, its focus on pioneering medical studies positions it as a platform for impactful contributions that can shape future healthcare policies and practices. The journal's open access policy ensures that vital research is freely available to a global audience, promoting accessibility and collaboration in the medical community.
BIODRUGS
Unlocking the Future of Medicine Through Innovative ResearchBIODRUGS is a prestigious academic journal published by ADIS INT LTD, specializing in the rapidly evolving fields of biotechnology, pharmacology, and medicine. Since its inception in 1997, this journal has established itself as a pivotal platform for disseminating cutting-edge research and comprehensive reviews that address both fundamental and clinical aspects of biopharmaceuticals. With an impressive impact factor and categorized within the prestigious Q1 quartile across multiple disciplines, including pharmacology and biotechnology, BIODRUGS ranks among the top in its field, reflecting its significant contributions to advancing knowledge. The journal's commitment to providing open access facilitates broad dissemination of its content, ensuring that researchers, professionals, and students can easily access critical insights and novel findings. The journal's scope extends well into 2024 and beyond, promising ongoing relevance and a continuous source of insightful academic discourse.
Pharmacy & Pharmacology-Farmatsiya i Farmakologiya
Connecting professionals to the latest in pharmaceutical sciences.Pharmacy & Pharmacology-Farmatsiya i Farmakologiya is a distinguished journal published by the Pyatigorskii Mediko-Farmatsevticheskii Inst in the Russian Federation, dedicated to advancing research in the fields of pharmacy and pharmacology. Since its transition to an Open Access format in 2013, it has become an invaluable resource for researchers and professionals seeking to disseminate and access high-quality findings. With its ISSN 2307-9266 and E-ISSN 2413-2241, this journal covers a broad range of topics, providing a platform for the latest developments in pharmaceutical sciences. It is noteworthy that, as of 2023, Farmatsiya i Farmakologiya is categorized in various quartiles, with its Q2 ranking in Pharmacology (nursing) and Q3 in Pharmacy indicating its growing impact and relevance within its field. With the journal's commitment to fostering innovation and collaboration in pharmacy and pharmacology research, it serves as an essential hub for academics, practitioners, and students aiming to contribute to and stay informed about the dynamic landscape of this critical discipline.
AMERICAN JOURNAL OF THERAPEUTICS
Exploring Breakthroughs in Medicine and PharmacologyThe American Journal of Therapeutics is a prominent academic journal published by Lippincott Williams & Wilkins, specializing in the fields of medicine and pharmacology. With a rich history originating from 1960 and a commitment to advancing therapeutic knowledge through peer-reviewed research, this journal serves as a vital resource for professionals, researchers, and students alike. Its strong impact factor, alongside its classification in the Q2 and Q3 quartiles for diverse categories in medicine and pharmacology, underscores its significance in the academic community. The journal engages with the latest findings and innovations in therapeutic approaches, offering a platform for discussion and dissemination of research that addresses critical healthcare challenges. Although it operates under a traditional subscription model, the journal aims to foster open discourse within the therapeutic landscape, making it essential reading for those dedicated to enhancing patient care and pharmaceutical practices.
CURRENT MEDICAL RESEARCH AND OPINION
Transforming Opinions into Evidence-Based Practices.CURRENT MEDICAL RESEARCH AND OPINION, published by Taylor & Francis Ltd, is a distinguished journal that has been at the forefront of medical research since its inception in 1972. With a vested interest in advancing healthcare knowledge, this journal encompasses a wide array of disciplines within the medical field, categorizing itself in Q2 of the Medicine (Miscellaneous) category according to the 2023 rankings. Notably, it holds a commendable rank of #119 out of 636 in the General Medicine category on Scopus, indicating its relevance and influence within the medical community, supported by an 81st percentile ranking. Although it does not present Open Access options, the comprehensive research articles, systematic reviews, and expert opinions it publishes are crucial for researchers, clinicians, and students who seek to deepen their understanding and drive innovations in medical practice. With its commitment to high-quality and impactful scientific communication, CURRENT MEDICAL RESEARCH AND OPINION remains an essential resource for those dedicated to advancing healthcare and improving patient outcomes.
International Journal of Clinical Pharmacy
Empowering Healthcare through Innovative Pharmaceutical ResearchThe International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.
Pharmacy
Fostering collaboration and innovation in drug discovery and application.Pharmacy is a premier open-access journal published by MDPI, dedicated to advancing research in the dynamic field of pharmaceutical sciences. Since its inception in 2013, this journal has become a vital platform for disseminating novel findings, reviews, and insights related to drug development, pharmacokinetics, pharmaceutical technology, and clinical applications. With an E-ISSN of 2226-4787, Pharmacy prioritizes accessibility and visibility, allowing researchers, professionals, and students from around the globe to engage with cutting-edge research without barriers. The journal plays a crucial role in shaping pharmaceutical education and practice, fostering innovative ideas and collaborative approaches aimed at improving health outcomes. As part of the MDPI family, Pharmacy is committed to maintaining high-quality standards, ensuring that all published articles undergo rigorous peer review.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Elevating standards in clinical pharmacy and patient care.JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.
Journal of Cardiovascular Translational Research
Bridging Innovation and Clinical Excellence in Cardiovascular HealthJournal of Cardiovascular Translational Research, published by Springer, is a pivotal platform in the fields of cardiology, genetics, and molecular medicine, dedicated to bridging the gap between experimental research and clinical application. With an impressive impact factor and a robust ranking—such as Rank #84/387 in Cardiology and Cardiovascular Medicine—this journal offers valuable insights and innovative research vital for understanding cardiovascular diseases and their implications. The journal spans a unique converged spectrum of topics, encompassing pharmaceutical sciences and genetic advancements, making it an essential resource for researchers, healthcare professionals, and students alike, striving for excellence in cardiovascular health. Although not open access, the journal ensures that cutting-edge research from 2008 to 2024 is readily available for a diverse readership eager to harness knowledge for clinical progress and improved patient outcomes.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Connecting Scholars to Advance the Science of PharmaceuticalsThe European Journal of Pharmaceutical Sciences is a prestigious academic journal dedicated to advancing the field of pharmaceutical science. Published by Elsevier, the journal boasts an impressive impact factor and is categorized in the Q1 quartile for pharmaceutical science as of 2023, signifying its influence and reputation within the academic community. With a Scopus ranking of #20 out of 183 in the fields of pharmacology, toxicology, and pharmaceutics, the journal provides a vital platform for researchers and practitioners to disseminate innovative studies and groundbreaking research that push the boundaries of drug development and delivery. Based in the Netherlands and operating since 1993, the journal seeks to cover a broad scope of topics related to pharmaceutical sciences, encouraging rigorous evaluations and discussions that enhance the understanding and application of this critical field. The absence of open access underscores the commitment to maintaining high scholarly standards, while still offering avenues for libraries and institutions to provide access to cutting-edge research. As the journal converges towards its 2024 milestones, it continuously aims to foster a vibrant exchange of knowledge among its diverse readership, comprising committed researchers, professionals, and students.